This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aclidinium bromide, LAS W 330, LAS34273, Tudorza/Eklira/Bretaris Genuair (EU/Japan), KRP-AB1102F
Description: LAS34273 is a long-acting M3 muscarinic acetylcholine receptor antagonist. Inhaled muscarinic antagonists block the effect of acetylcholine at its muscarinic receptor, leading to airway smooth muscle relaxation and bronchodilation.
The product is being developed in a Multi Dose-Dry Powder Inhaler (MDPI), Genuair. The Genuair inhaler was designed with a feedback system, which through a 'colored control window' and an audible click helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator and also incorporates safety features such as an anti-double-dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Forest and Almirall
In April 2006, Forest and Almirall entered an agreement to develop, market and distribute LAS34273 in the United States. Under terms of the agreement, Forest is making an upfront payment of $60 million to Almirall and will pay future undisclosed milestone payments.
In addition, Almirall receives royalty payments based on LAS34273 sales. Forest and Almirall will jointly oversee the development and regulatory approval of LAS34273 and share all expenses for current and future development programs. Almirall has granted Forest the rights of first negotiation for other Almirall respiratory products that could be combined with LAS34273. Forest will be responsible for sales and marketing of LAS34273 in the US and Almirall has retained an option to co-promote the product in the future while retaining commercialization rights for the rest of the world.
Kyorin and Almirall
In February 2011, Almirall and Kyorin Pharmaceutical Co....See full deal structure in Biomedtracker
Partners: Daewoong Pharmaceutical Company Ltd. The Menarini Group Quintiles Transnational Holdings, Inc. Allergan plc
Tudorza Pressair News
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: